AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of…
$2.23+5.69%
报价 2026-11-06
市值
$227M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -39.7%
$2.06$3.70
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ACIUAC Immune S.A. | $227M | +5.7% | – | 100% | – | – | – | |
| LXEOLexeo Therapeutics, Inc. Common Stock | $237.2M | -0.5% | -100.0% | 0% | – | – | – | |
| SRZNSurrozen, Inc. | $231.8M | +6.9% | +178.3% | 99.4% | – | – | – | |
| VNDAVanda Pharmaceuticals Inc. | $231M | +6.4% | +20.3% | 93.2% | – | – | – | |
| RNACCartesian Therapeutics, Inc. | $227.8M | +11.1% | -70.0% | 100% | – | – | – | |
| DRUGBright Minds Biosciences Inc. | $226.9M | +11.1% | – | 0% | – | – | – | |
| GLSIGreenwich LifeSciences, Inc. | $222.7M | +3.5% | – | 0% | – | – | – | |
| CABACabaletta Bio, Inc. | $220.4M | +1.6% | -43.2% | 0% | – | – | – | |
| KRROKorro Bio, Inc. | $217.2M | +0.1% | -61.8% | 72.8% | – | – | – | |
| 同行中位数 | – | – | -52.5% | 36.4% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 CHF（非美元）暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。